Última revisão: 30 Out 2020
Última atualização: 02 Set 2020

Resumo

Definição

História e exame físico

Principais fatores de diagnóstico

  • presença de fatores de risco
  • sintomas de armazenamento
  • sintomas de micção

Fatores de risco

  • idade superior a 50 anos
  • história familiar
  • raça não asiática
  • tabagismo
  • alopécia androgênica
  • síndrome metabólica

Exames diagnósticos

1° exames a serem solicitados

  • urinálise
  • antígeno prostático específico (PSA)
  • escore internacional de sintomas prostáticos (International Prostate Symptom Score)
  • escore de incômodo global
  • quadro de volume
Mais 1° exames a serem solicitados

Exames a serem considerados

  • ultrassonografia
  • tomografia computadorizada (TC) de abdome/pelve
  • cistoscopia
  • urofluxometria
  • estudo urodinâmico
Mais exames a serem considerados

Algoritmo de tratamento

Colaboradores

Michael T. Flannery

Professor

Internal Medicine

University of South Florida College of Medicine

Department of Internal Medicine

Tampa

FL

Divulgações

MTF declares that he has no competing interests.

Associate Professor and Program Director

Internal Medicine

University of South Florida College of Medicine

Department of Internal Medicine

Tampa

FL

Divulgações

EA declares that she has no competing interests.

Colegas revisoresMOSTRAR TODOS

Consultant Urological Surgeon

Royal Hallamshire Hospital

Honorary Senior Lecturer of Urology

University of Sheffield

Newcastle University

Visiting Professor of Urology

Sheffield Hallam University

Adjunct Secretary responsible for Education

European Association of Urology

Sheffield

UK

Divulgações

CRC is Chairman of NICE Male LUTS Guidelines Development Group.

Professor of Urology

Institute of Cellular Medicine

Newcastle University

Newcastle upon Tyne

UK

Divulgações

RP has received funding from the UK NHS (NIHR) to undertake commissioned reviews of treatment for benign prostatic enlargement.

Chief

Department of Surgery

South Seminole Hospital

Longwood

FL

Divulgações

SKB is a member of the National Speakers Bureau for Boehringer Ingelheim, Astellas Pharmaceutics, and Glaxo Pharmaceuticals and has served as a consultant for these companies.

O uso deste conteúdo está sujeito aos nossos avisos legais